Glynn Capital Management’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-12,701
| Closed | -$1.01M | – | 46 |
|
|
2025
Q2 | $1.01M | Sell |
12,701
-1,500
| -11% | -$119K | 0.23% | 34 |
|
|
2025
Q1 | $1.27M | Hold |
14,201
| – | – | 0.34% | 35 |
|
|
2024
Q4 | $1.41M | Hold |
14,201
| – | – | 0.33% | 35 |
|
|
2024
Q3 | $1.61M | Sell |
14,201
-8,867
| -38% | -$1.05M | 0.37% | 33 |
|
|
2024
Q2 | $2.86M | Hold |
23,068
| – | – | 0.58% | 30 |
|
|
2024
Q1 | $3.04M | Hold |
23,068
| – | – | 0.57% | 31 |
|
|
2023
Q4 | $2.51M | Hold |
23,068
| – | – | 0.47% | 34 |
|
|
2023
Q3 | $2.37M | Hold |
23,068
| – | – | 0.52% | 36 |
|
|
2023
Q2 | $2.66M | Hold |
23,068
| – | – | 0.59% | 31 |
|
|
2023
Q1 | $2.45M | Hold |
23,068
| – | – | 0.58% | 28 |
|
|
2022
Q4 | $2.56M | Hold |
23,068
| – | – | 0.62% | 32 |
|
|
2022
Q3 | $1.99M | Hold |
23,068
| – | – | 0.42% | 37 |
|
|
2022
Q2 | $2.1M | Hold |
23,068
| – | – | 0.44% | 37 |
|
|
2022
Q1 | $1.89M | Hold |
23,068
| – | – | 0.25% | 42 |
|
|
2021
Q4 | $1.77M | Hold |
23,068
| – | – | 0.19% | 42 |
|
|
2021
Q3 | $1.73M | Hold |
23,068
| – | – | 0.15% | 41 |
|
|
2021
Q2 | $1.79M | Sell |
23,068
-1,107
| -5% | -$82.3K | 0.16% | 37 |
|
|
2021
Q1 | $1.78M | Hold |
24,175
| – | – | 0.17% | 37 |
|
|
2020
Q4 | $1.89M | Hold |
24,175
| – | – | 0.18% | 37 |
|
|
2020
Q3 | $1.91M | Hold |
24,175
| – | – | 0.2% | 37 |
|
|
2020
Q2 | $1.78M | Hold |
24,175
| – | – | 0.22% | 33 |
|
|
2020
Q1 | $1.77M | Hold |
24,175
| – | – | 0.33% | 30 |
|
|
2019
Q4 | $2.1M | Hold |
24,175
| – | – | 0.37% | 27 |
|
|
2019
Q3 | $1.94M | Hold |
24,175
| – | – | 0.36% | 26 |
|
|
2019
Q2 | $1.93M | Hold |
24,175
| – | – | 0.33% | 25 |
|
|
2019
Q1 | $1.92M | Hold |
24,175
| – | – | 0.35% | 27 |
|
|
2018
Q4 | $1.76M | Hold |
24,175
| – | – | 0.38% | 25 |
|
|
2018
Q3 | $1.64M | Hold |
24,175
| – | – | 0.33% | 27 |
|
|
2018
Q2 | $1.4M | Hold |
24,175
| – | – | 0.3% | 27 |
|
|
2018
Q1 | $1.26M | Hold |
24,175
| – | – | 0.28% | 30 |
|
|
2017
Q4 | $1.3M | Hold |
24,175
| – | – | 0.28% | 30 |
|
|
2017
Q3 | $1.48M | Hold |
24,175
| – | – | 0.37% | 25 |
|
|
2017
Q2 | $1.48M | Hold |
24,175
| – | – | 0.4% | 27 |
|
|
2017
Q1 | $1.47M | Hold |
24,175
| – | – | 0.44% | 25 |
|
|
2016
Q4 | $1.36M | Hold |
24,175
| – | – | 0.46% | 25 |
|
|
2016
Q3 | $1.44M | Hold |
24,175
| – | – | 0.45% | 26 |
|
|
2016
Q2 | $1.33M | Hold |
24,175
| – | – | 0.43% | 29 |
|
|
2016
Q1 | $1.22M | Hold |
24,175
| – | – | 0.4% | 33 |
|
|
2015
Q4 | $1.22M | Hold |
24,175
| – | – | 0.38% | 30 |
|
|
2015
Q3 | $1.14M | Hold |
24,175
| – | – | 0.38% | 30 |
|
|
2015
Q2 | $1.31M | Hold |
24,175
| – | – | 0.42% | 30 |
|
|
2015
Q1 | $1.33M | Hold |
24,175
| – | – | 0.51% | 30 |
|
|
2014
Q4 | $1.31M | Hold |
24,175
| – | – | 0.46% | 30 |
|
|
2014
Q3 | $1.37M | Hold |
24,175
| – | – | 0.48% | 30 |
|
|
2014
Q2 | $1.33M | Hold |
24,175
| – | – | 0.43% | 31 |
|
|
2014
Q1 | $1.31M | Hold |
24,175
| – | – | 0.52% | 30 |
|
|
2013
Q4 | $1.16M | Hold |
24,175
| – | – | 0.4% | 33 |
|
|
2013
Q3 | $1.1M | Hold |
24,175
| – | – | 0.36% | 34 |
|
|
2013
Q2 | $1.07M | Buy |
+24,175
| New | +$1.08M | 0.43% | 31 |
|
Other funds holding MRK
Glynn Capital Management's MRK Position: Q3 2025 in Review
Glynn Capital Management sold out of Merck (MRK) in Q3 2025, closing a stake of 12,701 shares — an estimated $1.01M sold.
Glynn Capital Management first reported a position in MRK in Q2 2013 and held it in 49 quarters. The position peaked at $3.04M in Q1 2024. 3,309 funds tracked by Wall St. Rank hold MRK as of Q3 2025.
- Glynn Capital Management reported no remaining Merck position as of Q3 2025 after selling out during the quarter.
- Glynn Capital Management sold 12,701 Merck shares in Q3 2025, an estimated $1.01M.
- Glynn Capital Management first reported a position in Merck in Q2 2013 and held it in 49 quarters.
- Glynn Capital Management's Merck position peaked at $3.04M in Q1 2024.
- 3,309 funds tracked by Wall St. Rank held Merck as of Q3 2025.
Based on Glynn Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.